TickerFacts.

Kymera Therapeutics, Inc. (KYMR): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$8.31M
Year ended 2025-12-31
$8.23M
Trailing 12 months to 2026-06-30
+40.8%
3-year compound annual growth
+36.4%
5-year compound annual growth
2019-12-31: $825.0K2020-12-31: $1.76M2021-12-31: $2.40M2022-12-31: $2.98M2023-12-31: $3.56M2024-12-31: $7.37M2025-12-31: $8.31M$8.31M
2019-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$8.31M+12.7%2026-02-26, From 2025-01-01
2024-12-31$7.37M+106.8%2026-02-26, From 2024-01-01
2023-12-31$3.56M+19.8%2026-02-26, From 2023-01-01
2022-12-31$2.98M+24.2%2025-02-27, From 2022-01-01
2021-12-31$2.40M+36.0%2024-02-22, From 2021-01-01
2020-12-31$1.76M+113.7%2023-02-23, From 2020-01-01
2019-12-31$825.0Kn/a2022-02-24, From 2019-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Kymera Therapeutics, Inc. (KYMR)2025-12-31$8.31M+12.7%
Sangamo Therapeutics, Inc (SGMOQ)2025-12-31$3.96M-22.4%
C4 Therapeutics, Inc. (CCCC)2025-12-31$1.96M+7.8%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$1.28M+60.4%
Precision Biosciences Inc (DTIL)2025-12-31$1.47M-56.9%
Scilex Holding Co (SCLX)2025-12-31$4.62M+14.3%
Champions Oncology, Inc. (CSBR)2026-04-30$1.38M-16.0%
Vir Biotechnology, Inc. (VIR)2025-12-31$11.68M-19.8%
Alector, Inc. (ALEC)2025-12-31$5.72M+5.8%

Compare KYMR, SGMOQ, CCCC, XFOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗